FDA

#Awards #CN Bio #Collaboration #FDA #OBN Awards #Organ-on-a-chip

CN Bio named winner with most impactful industry collaboration  

CN Bio, an organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.   The award recognises the ongoing success of the company’s collaboration with the US Food and Drug Administration… Read More

#News

#Eli Lilly #FDA #MHRA #Obesity #Regulatory #Weight loss

Tirzepatide approved for weight management in US and UK

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2… Read More

#News #Regulatory #Trending News

Blood cells
#FDA #Gene mutation #Genetic diseases #Rare disease #Takeda

First therapy for very rare blood clotting disorder gets US greenlight

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making… Read More

#Editor's Choice #News #Regulatory

Mosquito
#Chikungunya virus #FDA #Immunology / Virology & Vaccines #Valneva

FDA approves world’s first chikungunya vaccine

The US Food and Drug Administration (FDA) has approved Ixchiq, Valneva’s single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus (CHIKV). The vaccine is indicated in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. Read More

#News #Trending News

Eye
#AMD #Endogena Therapeutics #FDA #Geographic atrophy #Ophthalmology

FDA gives green light for AMD treatment trials

The US Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. The company is currently… Read More

#News #Regulatory

HIV test
#FDA #HIV #Monoclonal antibodies #Theratechnologies

Results from HIV mAB intramuscular administration study 

Theratechnologies, a biopharmaceutical company focused on the development and commercialisation of innovative therapies, has announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their… Read More

#News

#Animal testing #ApconiX #Assays #FDA #Preclinical development

New podcast explores Sengenics’ i-Ome Discovery Microarrays

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More

#News

Lung cancer
#FDA #Non-small cell lung cancer (NSCLC) #Oncology #Orphan drugs #Pfizer

Orphan designated precision drug approved in US for NSCLC

The US Food and Drug Administration (FDA) has approved orphan drug encorafenib (Braftovi) with binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA also approved the FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics for encorafenib with… Read More

#News #Regulatory

Gastric cancer
#Antibody #FDA #Gastrointestinal #Oncology #Phase III trial #Stomach cancer #Transcenta

Antibody for gastric cancer progresses to Phase III trials

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2… Read More

#Cancer Research #News #Regulatory

Vaccine
#Covid-19 #Covid-19 vaccine #FDA #Immunology / Virology & Vaccines #Novavax #Omicron

Novavax Covid-19 vaccine updated for XBB.1.5 variant

Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US. The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and… Read More

#News

FDA approval
#Biologics #FDA #Rare disease #Rocket Pharmaceuticals

FDA acceptance advances investigational gene therapy 

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel).  Rocket Pharmaceuticals is a late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need. RP-L201 is a lentiviral vector… Read More

#News #Regulatory

#Drug approvals #FDA #Oncology #Rare disease

Positive data for 4SC’s CTCL treatment fuels marketing strategy  

Biotech company 4SC has announced positive new data for its treatment for patients with advanced-stage cutaneous T-cell lymphoma (CTCL).  Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL. The RESMAIN study is one of… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development #Sitting Down With podcast

Podcast: The FDA Modernisation Act 2.0 and seizure liability testing

The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as… Read More

#News

FDA headquarters
#Biologics / Biotechnology #FDA #Rare disease #Regulatory

FDA pilot programme to boost rare disease therapies

The US Food and Drug Administration (FDA) has announced a pilot programme with the aim of accelerating the development of novel drug and biological products for rare diseases. The agency is inviting a limited number of sponsors to participate in the programme, which allows for more frequent communication with FDA… Read More

#News #Regulatory

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance… Read More

#Podcasts